Skip to main content
SpringerLink
Log in

Antiretroviral Therapy for HIV Infection

A Knowledge-Based Approach to Drug Selection and Use

  • Disease Management
  • Published:
Drugs Aims and scope Submit manuscript

Summary

In the absence of evidence that eradication of HIV from an infected individual is feasible, the established goal of antiretroviral therapy is to reduce viral load to as low as possible for as long as possible. Achieving this with the currently available antiretroviral agents involves appropriate selection of components of combination regimens to obtain an optimal antiviral response. In addition, consideration of a plan for a salvage or second-line regimen is required if initial therapy fails to achieve an optimal response or should loss of virological control occur despite effective initial therapy. Such a planned approach, based on consideration of the likely modes of therapeutic failure (viral resistance, cellular resistance, toxicity) could be called rational sequencing.

Choice of therapy should never involve compromise in terms of activity. However, the choice of drug should also be guided by tolerability profiles and considerations of coverage of the widest range of infected cells, compartmental penetration, pharmacokinetic interactions and, importantly, the ability of an agent or combination to limit future therapeutic options through selection of cross-resistant virus. Available clinical end-point data clearly indicate that combination therapy is superior to monotherapy, with clinical and surrogate marker data supporting the use of triple drug (or double protease inhibitor) combinations over double nucleoside analogue combinations. Thus, 3-drug therapy should represent current standard practice in a nontrials setting.

Treatment should be considered as early as practical, and may be best guided by measurement of viral load, with a range of other markers having potential utility in individualising treatment decisions. Therapeutic failure may be defined clinically, immunologically or, ideally, virologically, and should prompt substitution of at least 2, and preferably all, components of the treatment regimen. Drug intolerance may also be best managed by rational substitution.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Wei X, Ghosh SK, Taylor ME, et al. Viral dynamics in human immunodeficiency virus type 1 infection. Nature 1995; 373: 117–22

    Article  PubMed  CAS  Google Scholar 

  2. Ho DD, Neumann AU, Perelson AS, et al. Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature 1995; 373: 123–6

    Article  PubMed  CAS  Google Scholar 

  3. Finzi D, Hermankova M, Pierson T, et al. Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy. Science 1997; 278: 1295–300

    Article  PubMed  CAS  Google Scholar 

  4. Emini EA, Holder DJ, Shivaprakash M, et al. The sustained suppression of circulating HIV-1 in indinavir-treated patients is a consequence of the complete prevention of new viral infection cycles. 6th European Conference on Clinical Aspects and Treatment of HIV-infection; 1997 Oct 11–15: Hamburg

  5. Kempf D, Rode R, Xu Y, et al. The durability of response to protease inhibitor therapy is predicted by viral load [abstract no. 62]. International Workshop on HIV Drug Resistance, Treatment Strategies and Eradication; 1997 Jun 25–28: St Petersburg (FL)

  6. Luizzi G, Chirianni A, Clementi M, et al. Analysis of HIV-1 load in blood, semen and saliva: evidence for different viral compartments in a cross-sectional and longitudinal study. AIDS 1996; 10: F51–6

    Article  Google Scholar 

  7. Sei S, Stewart SK, Farley M, et al. Evaluation of human immunodeficiency virus (HIV) type 1 RNA levels in cerebrospinal fluid and viral resistance to zidovudine in children with HIV encephalopathy. J Infect Dis 1996; 174: 1200–6

    Article  PubMed  CAS  Google Scholar 

  8. Deeks S, Grant R, Horton C, et al. Virologic effect of ritonavir (RTV) plus saquinavir (SQV) in subjects who have failed indinavir (IDV). 37th Interscience Conference on Antimicrobial Agents and Chemotherapy; 1997 Sep 28–Oct 1: Toronto

  9. Mohri H, Singh MK, Ching WTW, et al. Quantitation of zidovudine-resistant human immunodeficiency virus type 1 in the blood of treated and untreated patients. Proc Natl Acad Sci USA 1993; 90: 25–9

    Article  PubMed  CAS  Google Scholar 

  10. Nàjera I, Richman DD, Olivares I, et al. Natural occurrence of drug resistance mutations in the reverse transcriptase of human immunodeficiency virus type 1 isolates. AIDS Res Hum Retroviruses 1994; 10: 1479–88

    Article  PubMed  Google Scholar 

  11. Nàjera I, Holguin A, Quinones-Mateu E, et al. Pol gene quasispecies of human immunodeficiency virus: mutations associated with drug resistance in virus from patients undergoing no drug therapy. J Virol 1995; 69: 23–31

    PubMed  Google Scholar 

  12. Frost SDW, McLean AR. Quasispecies dynamics and the emergence of drug resistance during zidovudine therapy of HIV infection. AIDS 1994; 8: 323–32

    Article  PubMed  CAS  Google Scholar 

  13. Kellam P, Boucher CAB, Tijnagal JMGH, et al. Zidovudine treatment results in the selection of human immunodeficiency virus type 1 variants whose genotypes confer increasing levels of drug resistance. J Gen Virol 1994; 75: 341–51

    Article  PubMed  CAS  Google Scholar 

  14. Deeks S, Loftus R, Cohen P, et al. Incidence and predictors of virologic failure to indinavir (IDV) or/and ritonavir (RTV) in an urban health clinic. 37th Interscience Conference on Antimicrobial Agents and Chemotherapy; 1997 Sep 28–Oct 1: Toronto

  15. Conway B. The activity and safety of two formulations of saquinavir combined with two nucleosides in treatment-naive patients. 6th European Conference on Clinical Aspects and Treatment of HIV-infection; 1997 Oct 11–15: Hamburg

  16. BHIVA Guidelines co-ordinating committee. British HIV Association guidelines for antiretroviral treatment of HIV seropositive individuals. Lancet 1997; 349: 1086–92

    Article  Google Scholar 

  17. Carpenter CJ, Fischl MA, Hammer SM, et al. Antiretroviral therapy for HIV infection in 1997. JAMA 1997; 277: 1962–9

    Article  PubMed  CAS  Google Scholar 

  18. DeMasi R, Staszewski S, Dawson D, et al. Control of HIV-1 RNA prevents clinical disease progression to AIDS [abstract no. 105]. International Workshop on HIV Drug Resistance, Treatment Strategies and Eradication: 1997 Jun 25–28: St Petersburg (FL)

  19. Fischl MA, Richman DD, Greico MH, et al. The efficacy of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex: a double-blind, placebo controlled trial. N Engl J Med 1987; 317: 185–91

    Article  PubMed  CAS  Google Scholar 

  20. Fischl MA, Richman DD, Hansen N, et al. The safety and efficacy of zidovudine (AZT) in the treatment of subjects with mildly symptomatic human immunodeficiency virus type 1 (HIV) infection: a double-blind, placebo-controlled trial. Ann Intern Med 1990; 112: 727–37

    PubMed  CAS  Google Scholar 

  21. Volberding PA, Lagakos SW, Koch MA, et al. Zidovudine in asymptomatic human immunodeficiency virus infection — a controlled trial in persons with fewer than 500 CD4-positive cells per cubic millimeter. N Engl J Med 1990; 322: 941–9

    Article  PubMed  CAS  Google Scholar 

  22. Hamilton JD, Hartigan PM, Simberkoff MS, et al. Acontrolled trial of early versus late treatment with zidovudine in symptomatic human immunodeficiency virus infection. N Engl J Med 1992; 326: 437–43

    Article  PubMed  CAS  Google Scholar 

  23. Cooper DA, Gatell JM, Kroon S, et al. Zidovudine in persons with asymptomatic HIV infection and CD4+ cell counts greater than 400 per cubic millimeter. N Engl J Med 1993; 329: 297–303

    Article  PubMed  CAS  Google Scholar 

  24. Concorde Coordinating Committee. Concorde: MRC/ANRS randomized double-blind controlled trial of immediate and deferred zidovudine in symptom-free HIV infection. Lancet 1994; 343: 871–81

    Article  Google Scholar 

  25. Lenderking WR, Gelber RD, Cotton DJ, et al. Evaluation of the quality of life associated with zidovudine treatment in asymptomatic human immunodeficiency virus infection. N Engl J Med 1994; 330: 738–43

    Article  PubMed  CAS  Google Scholar 

  26. Volberding PA, Lagakos SW, Grimes JM, et al. The duration of zidovudine benefit in persons with asymptomatic HIV infection. JAMA 1994; 272: 437–42

    Article  PubMed  CAS  Google Scholar 

  27. Noticeboard: didanosine and ACTG 116A [editorial]. Lancet 1993; 341: 109

  28. Follansbee S, Drew L, Olsen R, et al. The efficacy of zalcitabine (ddC, HIVID) versus zidovudine (ZDV) as monotherapy in ZDV naïve patients with advanced HIV disease: a randomized, double-blind comparative trial (ACTG 114; N3300) [abstract no. PO-B26-2113]. IXth International Conference on AIDS and 4th World Congress on STD; 1993 Jun 7–11: Berlin

  29. Hammer S, Katzenstein D, Hughes, M. et al. A trial comparing nucleoside monotherapy with combination therapy in HIV-infected adults with CD4 cell counts from 200 to 500 per cubic millimeter. N Engl J Med 1996; 335: 1081–90

    CAS  Google Scholar 

  30. Katzenstein DA, Hammer SM, Hughes MD, et al. The relation of virologie and immunologie markers to clinical outcomes after nucleoside therapy in HIV-infected adults with 200 to 500 CD4 cells per cubic millimeter. N Engl J Med 1996; 335: 1091–8

    Article  PubMed  CAS  Google Scholar 

  31. Massari F, Staszewski S, Berry P, et al. A double-blind, randomized trial of indinavir (MK-639) alone or with zidovudine vs zidovudine alone in zidovudine naïve patients [abstract no. LB-6]. 35th Interscience Conference on Antimicrobial Agents and Chemotherapy; 1995 Sep 17–20: San Francisco

  32. Massari F, ConantM, Mellors J. Aphase II open-label, randomized study of the triple combination of indinavir, zidovudine, and didanosine versus indinavir alone and zidovudine/didanosine in antiretroviral naïve patients [abstract no. 90]. 3rd Conference on Retroviruses and Opportunistic Infections: 1996 Jan 28: Washington, D.C.

  33. Danner SA, Carr A, Leonard JM, et al. Safety, pharmacokinetics and antiviral activity of ritonavir, an inhibitor of HIV-1 protease [abstract no. 75]. 4th International Workshop on HIV Drug Resistance; 1995 Jul 6–9: Sardinia, Italy

  34. Danner SA, Carr A, Leonard JM, et al. A short-term study of the safety, pharmacokinetics, and efficacy of ritonavir, an inhibitor of HIV-1 protease. N Engl J Med 1995: 333: 1528–33

    Article  PubMed  CAS  Google Scholar 

  35. Markowitz M, Saag M, Powderly WG, et al. A preliminary study of ritonavir, an inhibitor of HIV-1 infection. N Engl J Med 1995; 333: 1534–9

    PubMed  CAS  Google Scholar 

  36. Molla A, Korneyeva M, Gao Q. Ordered accumulation of mutations in HIV protease confers resistance to ritonavir. Nature Med 1996; 2: 760–6

    Article  PubMed  CAS  Google Scholar 

  37. Norbeck D, Hsu A, Granneman R, et al. Virologie and immunologie response to ritonavir (ABT-538), an inhibitor of HIV protease [abstract no. 70]. 4th International Workshop on HIV Drug Resistance; 1995 Jul 6–9; Sardinia, Italy

  38. Markowitz M, Conant M, Hurley A, et al. Phase I/II dose range-finding study of the HIV protease inhibitor Ag 1343 [abstract no. LB-4]. 35th Interscience Conference on Antimicrobial Agents and Chemotherapy; 1995 Sep 17–29: San Francisco

  39. Moyle G, Youle M, Chapman S, et al. A Phase II dose-escalation study of the Agouron protease inhibitor Ag 1343 [abstract no. LB-3]. 35th Interscience Conference on Antimicrobial Agents and Chemotherapy; 1995 Sep 17–20: San Francisco

  40. Schapiro JM, Winters MA, Stewart F, et al. The effect of high-dose saquinavir on viral load and CD4: pl T-cell counts in HIV-infected patients. Ann Intern Med 1996; 124: 1039–50

    PubMed  CAS  Google Scholar 

  41. Delta Coordinating Committee. Delta: a randomised double-blind controlled trial comparing combinations of zidovudine plus didanosine or zalcitabine with zidovudine alone in HIV-infected individuals. Lancet 1996; 348: 283–91

    Article  Google Scholar 

  42. CAESAR Coordinating Committee. Randomised trial of addition of lamivudine or lamivudine plus loviride to zidovudine-containing regimens for patients with HIV-1 infection: the CAESAR trial. Lancet 1997; 349: 1413–21

    Article  Google Scholar 

  43. Hammer SM, Hughes MD, Squires K, et al. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. N Engl J Med 1997; 337: 725–33

    Article  PubMed  CAS  Google Scholar 

  44. Loveday C, Devereux H, Burke A, et al. Acomparison of HIV-1 RNA load assays for baseline values prior to commencing therapy in a clinic population with epidemiological evidence of non-clade B virus [abstract no. 45]. International Workshop on HIV Drug Resistance, Treatment Strategies and Eradication; 1997 Jun 25–28: St Petersburg (FL)

  45. Opravil M, DeMasi R, Hill A. Prediction of long-term HIV RNA suppression during zidovudine/lamivudine treatment [abstract no. 60]. International Workshop on HIV Drug Resistance, Treatment Strategies and Eradication; 1997 Jun 25–28: St Petersburg (FL)

  46. Borleffs JCC, Boucher CAB, Schuurman R, et al. Saquinavir-soft gelatin capsules versus indinavir as part of AZT and 3TC containing triple therapy. 6th European Conference on Clinical Aspects and Treatment of HIV-infection; 1997 Oct 11–15: Hamburg

  47. Posniak A. Study of protease inhibitors in combination in Europe (SPICE). 6th European Conference on Clinical Aspects and Treatment of HIV-infection; 1997 Oct 11–15: Hamburg

  48. Murphy R, Pottage J, Peterson D, et al. A 15-site, open-label, randomized, comparative study of stavudine + didanosine + indinavir versus zidovudine + lamivudine + indinavir in treatment naïve HlV-infected patients. 6th European Conference on Clinical Aspects and Treatment of HIV-infection; 1997 Oct 11–15: Hamburg

  49. Gulick R, Santana J, Squires K, et al. A 15-site, open-label, randomized, comparative study of stavudine + lamivudine + indinavir versus zidovudine + lamivudine + indinavir in treatment naïve HlV-infected patients. 6th European Conference on Clinical Aspects and Treatment of HIV-infection; 1997 Oct 11–15: Hamburg

  50. Moyle GJ, Gazzard BG. The role of stavudine in the management of adults with HIV infection. Antiviral Ther 1997; 2: 207–18

    CAS  Google Scholar 

  51. Conway B, Montaner JSG, Cooper D, et al. Randomised double blind one year study of the immunological and virological effects of nevirapine, didanosine and zidovudine combinations among antiretroviral naïve, AIDS-free patients with CD4 200-600 [abstract no. OP7.2]. AIDS 1996; 10 Suppl. 2: S15

    Google Scholar 

  52. Murphy RL, Montaner J. Nevirapine: a review of its development, pharmacological profile and potential for clinical use. Exp Opin Invest Drugs 1996; 5: 1183–99

    Article  CAS  Google Scholar 

  53. Hicks C, Hass D, Seekins D, et al. A phase II, double-blind, placebo-controlled, dose-ranging study to assess the antiretroviral activity and safety of DMP 266 (Efavirenz, Sustiva) in combination with open label zidovudine (ZDV) with lamivudine [abstract no. 920]. 6th European Conference on Clinical Aspects and Treatment of HIV-infection; 1997 Oct 11–15: Hamburg

  54. Mathez D, Bagnarelli P, Gorin I, et al. Reductions in viral load and increases in T lymphocyte numbers in treatment-naïve patients with advanced HIV-1 infection treated with ritonavir, zidovudine, and zalcitabine triple therapy. Antiviral Ther 1997; 2: 175–83

    CAS  Google Scholar 

  55. Saag M, Knowles M, Chang Y, et al. Durable effect of VIRACEPT (nelfinavir mesylate) in triple combination therapy. Infectious Diseases Society of America Annual Meeting; 1997 Sep 13–16: San Francisco

  56. Cameron DW, Heath-Chiozzi M, Kravcik S. Prolongation of life and prevention of AIDS complications in advanced HIV immunodeficiency with ritonavir: update [abstract no. Mo.B.411]. Xlth International Conference on AIDS; 1996 Jul 7–12: Vancouver

  57. Heath-Chiozzi M, Leonard J, Sun E, et al. Ritonavir clinical benefit correlates with HIV RNA and CD4 cell levels in advanced HIV illness [abstract no. We.B.3127]. Xlth International Conference on AIDS; 1996 Jul 7–12: Vancouver

  58. Hammer SM, Squires KE, Hughes MD, et al. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. N Engl J Med 1997; 337: 725–33

    Article  PubMed  CAS  Google Scholar 

  59. Gulick RM, Mellors JW, Havlir D, et al. Treatment with indinavir, zidovudine and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy. N Engl J Med 1997; 337: 734–9

    Article  PubMed  CAS  Google Scholar 

  60. Mayers D, Riddler S, Bach M, et al. Durable clinical activity and tolerability for DMP 266 in combination with indinavir (IDV) at 24 weeks [abstract no. 1-175]. 37th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC); 1997 Sep 28–Oct 1: Toronto

  61. PedneaultL, Elion R, Adler M, et al. Stavudine, didanosine, and nelfinavir combination therapy in HIV-infected subjects: antiviral effect and safety in an ongoing pilot study. 4th Conference on Retroviruses and Opportunistic Infections; 1997 Jan 22–26: Washington, DC

  62. Hirsch M, Meilbohm A, Rawlins A, et al. Indinavir in combination with zidovudine and lamivudine in ZDV-experienced patients with CD4 counts <50 cells/mm3. 4th Conference on Retroviruses and Opportunistic Infections; 1997 Jan 22–26: Washington, DC

  63. Harris M, Rachlis A, Shillington A, et al. Long-term suppression of HIV in plasma with a combination of two nucleosides and nevirapine (NVP). 6th European Conference on Clinical Aspects and Treatment of HIV-infection; 1997 Oct 11–15: Hamburg

  64. Pakker N, Kroon E, Hall D, et al. Functional capacity of T cells and immunological response in naïve HIV-1 patients treated with combinations of reverse transcriptase inhibitors [abstract no. OP2.1]. AIDS 1996; 10 Suppl. 2: S10

    Google Scholar 

  65. Ruiz NM, Manion DJ, Labriola DF, et al. HIV-1 suppression to ‘<1 copy/mL’ by Amplicor assay in patients receiving indinavir +/- DMP 266 (efavirenz): results of DMP 266-003, cohort IV [abstract no. 921]. 6th European Conference on Clinical Aspects and Treatment of HIV-infection; 1997 Oct 11–15: Hamburg

  66. Gao WY, Johns DG, Mitsuya H. Anti-HIV-1 activity of hydroxyurea in combination with 2′,3′-dideoxynucleosides. Mol Pharmacol 1994; 46: 767–72

    PubMed  CAS  Google Scholar 

  67. Biron F, Lucht F, Peyramond D, et al. Anti-HIV activity of the combination of didanosine and hydroxyurea in HIV-1-infected individuals. J Acquir Immune Defic Syndr 1995; 10: 36–40

    CAS  Google Scholar 

  68. Montaner JSG, Zala C, Raboud JM, et al. A pilot study of hydroxyurea (HO-urea) as adjuvant therapy among patients with advanced HIV disease receiving didanosine (ddl) therapy [abstract no. 406]. 3rd Conference on Retroviruses and Opportunistic Infections; 1996 Jan 28; Washington, DC

  69. Molla A, Korneyeva M, Chernyavskiy T, et al. Characterization of HIV-1 protease mutations, compliance and drug concentrations in patients who have HIV RNA rebound on ritonavir/saquinavir. International Workshop on HIV Drug Resistance, Treatment Strategies and Eradication; 1997 Jun 25–28: St Petersburg (FL)

  70. Bodsworth NJ, Heaps M, Gosling D, et al. Efficacy of indinavir (IDV) and ritonavir (RTV) in patients pretreated with saquinavir [abstract]. 7th International Antiviral Symposium; 1997 Feb 17–19: Sydney

  71. Novak RM, Colombo J, Linares-Diaz M, et al. Comparison of AZT/3TC VS. D4T/3TC for the treatment of HIV in persons with CD4 counts <300 and prior AZT experience [abstract no. Tu.B. 2132]. Xlth International Conference on AIDS; 1996 Jul 7–12: Vancouver

  72. Kahn JO, Lagakos SW, Richman DD, et al. A controlled trial comparing continued zidovudine with didanosine in human immunodeficiency virus infection. N Engl J Med 1992; 327: 581–7

    Article  PubMed  CAS  Google Scholar 

  73. Holodniy M, Katzentein D, Mole L, et al. Human immunodeficiency virus reverse transcriptase Codon 215 mutations diminish virologic response to didanosine-zidovudine therapy in subjects with non-syncytium-inducing viral phenotype. J Infect Dis 1996; 174: 854–7

    Article  PubMed  CAS  Google Scholar 

  74. Fischl MA, Stanley K, Collier AC, et al. Combination and monotherapy with zidovudine and zalcitabine in patients with advanced HIV disease. Ann Intern Med 1995; 122: 24–32

    PubMed  CAS  Google Scholar 

  75. Abrams DI, Goldman A, Launer C, et al. A comparative trial of didanosine or zidovudine after treatment with zidovudine in patients with human immunodeficiency virus infection. N Engl J Med 1994; 330: 657–62

    Article  PubMed  CAS  Google Scholar 

  76. Spruance SL, Pavia AT, Mellors JW, et al. Clinical efficacy of monotherapy with stavudine compared with zidovudine in HIV-infected, zidovudine-experienced patients: a randomized, double-blind, controlled trial. Bristol-Myers Squibb Stavudine/019 Study Group. Ann Intern Med 1997; 126: 355–63

    CAS  Google Scholar 

  77. Japour AJ, Welles S, D’Aquila RT, et al. Prevalence and clinical significance of zidovudine resistance mutations in human immunodeficiency virus isolated from patients after long-term zidovudine treatment. J Infect Dis 1995; 171: 1172–9

    Article  PubMed  CAS  Google Scholar 

  78. Lalezari J, Haubrich R, Burger HU, et al. Improved survival and decreased progression of HIV in patients treated with saquinavir and zalcitabine [abstract no. LB.B. 6033]. Xlth International Conference on AIDS; 1996 Jul 7–12: Vancouver

  79. Davey RT, Chaitt DG, Reed GF, et al. Randomized, controlled phase I/II trial of combination therapy with delavirdine (U-90152S) and conventional nucleosides in human immunodeficiency virus type-1 infected patients. Antimicrob Agents Chemother 1996; 40: 1657–64

    PubMed  CAS  Google Scholar 

  80. Sylvester S, Caliendo A, An D, et al. HIV-1 resistance mutations and plasma RNA during ZDV+ddC combination therapy [abstract]. J Acquir Immune Defic Syndr Hum Retrovirol 1995; 10 Suppl. 3: 23

    Google Scholar 

  81. Schooley RT, Ramirez-Ronda C, Lange JMA. Virologic and immunologie benefits of initial combination therapy with zidovudine and zalcitabine or didanosine compared with zidovudine monotherapy. J Infect Dis 1996; 173: 1354–66

    Article  PubMed  CAS  Google Scholar 

  82. Quinones-Mateu ME. A unique mechanism for zidovudine-resistance and evidence for a zidovudine-mediated cross-resistance to other nucleoside analogues by zidovudine-resistant viruses [abstract no. 10]. International Workshop on HIV Drug Resistance, Treatment Strategies and Eradication; 1997 Jun 25–28: St Petersburg (FL)

  83. Kleim JP, Pauosner M, Winkler I, et al. Nucleoside reverse transcriptase inhibitor-specific mutations within the HIV-1 pol gene selected with a non-nucleoside type RT inhibitor [abstract]. J Acquir Immune Defic Syndr Hum Retrovirol 1995; 10 Suppl. 3: 2

    Google Scholar 

  84. Shirasaka T, Kavlick MF, Veno T, et al. Emergence of human immunodeficiency virus type 1 variants with resistance to multiple dideoxynucleosides in patients receiving therapy with dideoxynucleosides. Proc Natl Acad Sci USA 1995; 92: 2398–402

    Article  PubMed  CAS  Google Scholar 

  85. Para MF, Collier A, Coombs R, et al. ACTG 333: antiviral effects of switching from saquinavir hard capsules (SQVhc) to saquinavir soft gelatin capsule (SQVsgc) vs switching to indinavir (IDV) after prior saquinavir [abstract no. 299]. Infectious Diseases Society of America Annual Meeting; 13–16 Sep 1997: San Francisco

  86. Schapiro J, Winters M, Lawrence J, et al. Clinical and genotypic cross-resistance between the protease inhibitors saquinavir and indinavir. International Workshop on HIV Drug Resistance, Treatment Strategies and Eradication; 1997 Jun 25–28; St Petersburg (FL)

  87. Dulioust A, Paulous S, Guillemot L, et al. Selection of saquinavir-resistant mutants by indinavir following a switch from saquinavir [abstract no. 16]. International Workshop on HIV Drug Resistance, Treatment Strategies and Eradication; 1997 Jun 25–28: St Petersburg (FL)

  88. Lawrence J, Schapiro J, Pesano R, et al. Clinical response and genotypic resistance patterns of sequential therapy with nelfinavir followed by indinavir plus nevirapine in saquinavir/reverse transcriptase inhibitor-experienced patients [abstract no. 64]. International Workshop on HIV Drug Resistance, Treatment Strategies and Eradication; 1997 Jun 25–28: St Petersburg

  89. Pym AS, Churchill DR, Galpin S, et al. Presence of mutation at codon 90 may predict response to ritonavir/saquinavir combination in HIV seropositive patients pretreated with saquinavir monotherapy [abstract no. 84]. International Workshop on HIV Drug Resistance, Treatment Strategies and Eradication; 1997 Jun 25–28: St Petersburg (FL)

  90. Walmsley S, Clark J, Salti I, et al. Can protease inhibitors be used sequentially in patients with advanced HIV infection [abstract no. 1-189]. 37th Interscience Conference on Antimicrobial Agents and Chemotherapy; 28 Sep–1 Oct 1997: Toronto

  91. Miller V, Hertogs K, de Bethune M-P, et al. Incidence of HIV-1 resistance and cross-resistance to protease inhibitors after indinavir failure: impact on subsequent ritonavir/saquinavir combination therapy [abstract no. 81]. International Workshop on HIV Drug Resistance, Treatment Strategies and Eradication; 1997 Jun 25–28: St Petersburg (FL)

  92. Alpha International Coordinating Committee. The Alpha trial: European/Australian randomized double-blind trial of two doses of didanosine in zidovudine intolerant patients with symptomatic HIV disease. AIDS 1996; 10(8): 867–80

    Article  Google Scholar 

  93. Allan JD, De Gruttola V, Cross A, et al. An efficacy study of 23-dideoxyinosine (ddl) (BMY-40900) administered orally twice daily to zidovudine intolerant patients with HIV infections (ACTG 118) [abstract no. WS-B24-2]. IXth International Conference on AIDS and 4th World Congress on STD; 7–11 June 1993: Berlin

  94. Moyle GJ, Nelson MR, Hawkins D, et al. The use and toxicity of didanosine (ddl) in HIV antibody positive individuals intolerant to zidovudine (AZT). Q J Med 1993; 86: 155–63

    PubMed  CAS  Google Scholar 

  95. Abrams DI, Goldman AI, Launer C, et al. A comparative trial of didanosine or zalcitabine after treatment with zidovudine in patients with human immunodeficiency virus infection. N Engl J Med 1994; 330: 657–62

    Article  PubMed  CAS  Google Scholar 

  96. Moyle G, Goll A, Snape S, et al. Safety and tolerability of zalcitabine (ddC) in patients with AIDS or advanced AIDS-related complex in the European Expanded Access Programme. Int J Antimicrob Agents 1996; 7: 41–8

    Article  PubMed  CAS  Google Scholar 

  97. Farthing C, Japour A, Cohen C, et al. Cerebrospinal fluid (CSF) and plasma HIV RNA suppression with ritonavir (RIT)-saquinavir (SQV) in protease inhibitor naïve patients [abstract no. LB3]. 37th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC); 28 Sep–1 Oct 1997: Toronto

  98. Cohen C, Sun E, Cameron D, et al. Ritonavir-saquinavir combination treatment in HIV-infected patients [abstract no. LB7b]. 36th Interscience Conference on Antimicrobial Agents and Chemotherapy; 15–18 Sep 1996: New Orleans

  99. Gazzard BG, Moyle GJ. Individualisation of HIV therapy: the clinician’s perspective. Br J Clin Prac 1995; 49: 145–7

    CAS  Google Scholar 

  100. O’Brien WA, Hartigan PM, Martin D, et al. Changes in plasma HIV-1 RNA and CD4+ lymphocyte counts and the risk of progression to AIDS. N Engl J Med 1996; 334: 426–31

    Article  PubMed  Google Scholar 

  101. Keilbaugh SA, Prusoff WH, Simpson MV. The PC12 cell as a model for studies of the mechanism of induction of peripheral neuropathy by anti-HIV 1-dideoxynucleoside analogs. Biochem Pharmacol 1991; 42: R5–8

    Article  PubMed  CAS  Google Scholar 

  102. LeLacher SF, Simon GI. Exacerbation of dideoxycytidine-induced neuropathy with dideoxyinosine. J Acquir Immune Defic Syndr 1991; 4: 538–9

    Google Scholar 

  103. Cupler EJ, Dalakas MC. Exacerbation of peripheral neuropathy by lamivudine. Lancet 1995; 345: 460–1

    Article  PubMed  CAS  Google Scholar 

  104. Gazzard BG, Moyle GJ. The role of didanosine in the management of HIV-1 infection. Antiviral Therapy 1997; 2(3): 135–47

    PubMed  CAS  Google Scholar 

  105. Sahai J. Risks and synergies from drug interactions. AIDS 1996; 10 Suppl. 1: S21–5

    PubMed  CAS  Google Scholar 

  106. Adkins JC, Peters DH, Faulds D. Zalcitabine: an update of its pharmacodynamic and pharmacokinetic properties and clinical efficacy in the management of HIV infection. Drugs 1997 Jun; 53(6): 1054–80

    Article  PubMed  CAS  Google Scholar 

  107. Ferry JJ, Herman BD, Cox SR, et al. Delavirdine (DLV) and indinavir (IDV): a pharmacokinetic drug-drug interaction study in healthy adult volunteers [abstract]. 4th Conference on Retroviruses and Opportunistic Infections: 1997 Jan 22–26; Washington, DC

  108. Cox SR, Batts DH, Stewart F, et al. Evaluation of the pharmacokinetic interaction between saquinavir and delavirdine in healthy volunteers [abstract]. 4th Conference on Retroviruses and Opportunistic Infections: 1997 Jan 22–26; Washington, DC

  109. Kravcik S, Sahai J, Kerr B, et al. Nelfinavir mesylate increases saquinavir soft gel capsule exposure in HIV patients [abstract]. 4th Conference on Retroviruses and Opportunistic Infections: 1997 Jan 22–26; Washington, DC

  110. Lea AP, Faulds D. Ritonavir. Drugs 1996 Oct; 52(4): 541–6

    Article  PubMed  CAS  Google Scholar 

  111. Cato A, Cavanaugh J, Shi H, et al. Assessment of multiple doses of ritonavir on the pharmacokinetics of rifabutin [abstract no. Mo.B.1199]. Xlth International Conference on AIDS; 1996 Jul 7–12: Vancouver

  112. Bertz R, Cao G, Cavanaugh J, et al. Effect of ritonavir on the pharmacokinetics of desipramine [abstract no. Mo.B.1201]. Xlth International Conference on AIDS; 1996 Jul 7–12: Vancouver

  113. Ouellet D, Hsu A, Qian J, et al. Effect of ritonavir on the pharmacokinetics of ethinylestradiol in healthy female volunteers [abstract no. Mo.B.1198]. Xlth International Conference on AIDS; 1996 Jul 7–12: Vancouver

  114. Hsu A, Granneman GR, Witt G, et al. Assessment of multiple doses of ritonavir on the pharmacokinetics of theophylline [abstract no. Mo.B.1200]. Xlth International Conference on AIDS; 1996 Jul 7–12: Vancouver

  115. Yven G, Anderson R, Daniels R, et al. Investigation of nelfinavir mesylate pharmacokinetic interactions with indinavir and ritonavir [abstract]. 4th Conference on Retroviruses and Opportunistic Infections; 1997 Jan 22–26: Washington, DC

  116. McCrea J, Buss N, Stone J, et al. Indinavir-saquinavir single dose pharmacokinetic study [abstract]. 4th Conference on Retroviruses and Opportunistic Infections; 1997 Jan 22–26: Washington, DC

  117. Kerr B, Yven G, Daniels R, et al. Strategic approach to nelfinavir mesylate drug interactions involving CYP3A metabolism [abstract]. 4th Conference on Retroviruses and Opportunistic Infections; 1997 Jan 22–26: Washington, DC

  118. Back DJ, Haggard PG, Veal GJ, et al. Intracellular phosphorylation interactions between nucleoside analogues [abstract no. 41]. 5th European Conference on Clinical Aspects and Treatment of HIV Infection; 1995: Copenhagen

  119. Ruiz L, Romeu J, Martainez-Picado J, et al. Efficacy of triple combination therapy with zidovudine (ZDV) plus zalcitabine (ddC) plus lamivudine (3TC) versus double (ZDV/3TC) combination therapy in patients previously treated with ZDV/ddC. AIDS 1996; 10: F61–6

    Article  PubMed  CAS  Google Scholar 

  120. Stretcher BN, Pesce AJ, Frame PT, et al. Correlates of zidovudine phosphorylation with markers of HIV disease: progression and drug-toxicity. AIDS 1994; 8: 763–9

    Article  PubMed  CAS  Google Scholar 

  121. Johnson VA. Combination therapy: more effective control of HIV type 1? AIDS Res Hum Retrovirol 1994; 8: 907–12

    Article  Google Scholar 

  122. Merrill DP, Moonis M, Chou T-C, et al. Lamivudine or stavudine in two- and three-drug combinations against human immunodeficiency virus type 1 replication in vitro. J Infect Dis 1996; 173: 355–64

    Article  PubMed  CAS  Google Scholar 

  123. Merrill DP, Manion DJ, Chou T-C, et al. Protease inhibitor combination regimens against HIV-1 in vitro. 4th Conference on Retroviruses and Opportunistic Infections; 1997 Jan 22–26: Washington, DC

  124. Gao WY, Agbaria R, Driscoll JS, et al. Divergent anti-human immunodeficiency virus activity and anabolic phosphorylation of 23-dideoxynucleoside analogs in resting and activated human cells. J Biol Chem 1994; 269: 12633–8

    PubMed  CAS  Google Scholar 

  125. Koot M, Keet IPM, Vos AHV, et al. Prognostic value of HIV-1 syncytium-inducing phenotype for rate of CD4+ cell depletion and progression to AIDS. Ann Intern Med 1993; 118: 681–8

    PubMed  CAS  Google Scholar 

  126. Richman DD, Bozette SA. The impact of syncytium-inducing phenotype of human immunodeficiency virus on disease progression. J Infect Dis 1994; 169: 968–74

    Article  PubMed  CAS  Google Scholar 

  127. Schellekens PTA, Koot M, Roos MTL, et al. Immunologic and virologic markers determining progression to AIDS. J Acquir Immune Defic Syndr 1995; 10 Suppl. 2: S62–6

    Google Scholar 

  128. Delforge M-L, Liesnard C, Debaisieux L, et al. In vivo inhibition of syncytium-inducing variants of HIV in patients treated with didanosine. AIDS 1995; 9: 89–90

    Article  PubMed  CAS  Google Scholar 

  129. Moyle G. Saquinavir: a review of its development, pharmacological properties and clinical use. Exp Opin Invest Drugs 1996; 5: 155–67

    Article  CAS  Google Scholar 

  130. Epstein LG, Kuiken C, Blumberg BM, et al. HIV-1 V3 domain variation in brain and spleen of children with AIDS: tissue-specific evolution within host-determined quasispecies. Virology 1991; 180: 583–90

    Article  PubMed  CAS  Google Scholar 

  131. Ball JK, Holmes EC, Whitwell H, et al. Genomic variation of human immunodeficiency virus type-1 (HIV-1): molecular analysis of HIV-1 in sequential blood samples and various organs obtained at autopsy. J Gen Virol 1994; 75: 867–79

    Article  CAS  Google Scholar 

  132. Haggerty S, Stevenson M. Predominance of distinct viral genotypes in brain and lymph node compartments of HIV-1-infected individuals. Viral Immunol 1991; 4: 123–31

    Article  PubMed  CAS  Google Scholar 

  133. Wildemann B, Haas J, Ehrhart K, et al. In vivo comparison of zidovudine resistance mutations in blood and CSF of HIV-1 infected patients both simultaneously in plasma but also between different body compartments such as blood and CSF. Neurology 1993; 43: 2659–63

    Article  PubMed  CAS  Google Scholar 

  134. Portegies P. AIDS dementia complex: a review. J Acquir Immune Defic Syndr 1994; 7 Suppl. 2; S38–49

    PubMed  Google Scholar 

  135. Di Stephano M, Norkrans G, Chiodi F, et al. Zidovudine-resistant variants of HIV-1 in brain [letter]. Lancet 1993; 342: 865

    Article  Google Scholar 

  136. Foudraine N, de Wolf F, Hoetelmans R, et al. CSF and serum HIV-RNA during AZT/3TC and d4T/3TC treatment. 4th Conference on Retroviruses and Opportunistic Infections; 1997 Jan 22–26: Washington, DC

  137. Collier AC, Marra C, Coombs RW, et al. Cerebrospinal fluid (CSF) indinavir (IDV) and HIV RNA levels in patients on chronic indinavir therapy [abstract no. 286]. Infectious Diseases Society of America Annual Meeting: 13–16 Sep 1997: San Francisco

  138. Moyle GJ, Sadler M, Buss N, et al. Correlation between plasma and CSF viral load in patients on saquinavir containing regimens: pharmacokinetics (PK) of saquinavir at steady state in CSF and plasma [abstract no. 249]. 6th European Conference on Clinical Aspects and Treatment of HIV-infection; 1997 Oct 11–15: Hamburg

  139. Moyle GJ. Use of viral resistance patterns to antiretroviral drugs in optimising selection of drug combinations and sequences. Drugs 1996 Aug; 52(2): 168–85

    Article  PubMed  CAS  Google Scholar 

  140. Moyle G. Influence of emergence of viral resistance on HIV treatment choice. Int J STD AIDS 1995; 6: 225–6

    PubMed  CAS  Google Scholar 

  141. Moyle GJ. Current knowledge of HIV-1 reverse transcriptase (RT) mutations selected during nucleoside analogue therapy: the potential to use resistance data to guide clinical decisions. J Antimicrob Chemother 1997; 40: 765–77

    Article  PubMed  CAS  Google Scholar 

  142. D’Aquila RT, Johnson VA, Welles SL, et al. Zidovudine resistance and HIV-1 disease progression during antiretroviral therapy. Ann Intern Med 1995; 122: 401–8

    PubMed  Google Scholar 

  143. Tremblay M, Rooke R, Wainberg MA. Zidovudine-resistant and -sensitive HIV-1 isolates from patients on drug therapy: in vitro studies evaluating level of replication-competent viruses and cytopathogenicity. AIDS 1992; 6: 1445–9

    Article  PubMed  CAS  Google Scholar 

  144. Caliendo A, Savara A, An D. Zidovudine-resistance mutations increase replication in drug-free PBMC stimulated after infection [abstract]. J Acquir Immune Defic Syndr Hum Retrovirol 1995; 10 Suppl. 3: 2–3

    Google Scholar 

  145. Mayers DL, Japour AJ, Arduino J-M, et al. Dideoxynucleoside resistance emerges with prolonged zidovudine therapy. Antimicrob Agents Chemother 1994; 38: 307–14

    Article  PubMed  CAS  Google Scholar 

  146. Rooke R, Parniak MA, Tremblay M, et al. Biological comparisons of wild-type and zidovudine-resistant isolates of human immunodeficiency virus type 1 from the same subjects: susceptibility and resistance to other drugs. Antimicrob Agents Chemother 1991; 35: 988–91

    Article  PubMed  CAS  Google Scholar 

  147. Dianzani F, Antonelli G, Turriziani O, et al. Zidovudine induces the expression of cellular resistance affecting its antiviral activity. AIDS Res Hum Retroviruses 1994; 10: 1471–8

    Article  PubMed  CAS  Google Scholar 

  148. Kozal MJ, Kroodsma K, Winters MA, et al. Didanosine resistance in HIV-infected patients switched from zidovudine to didanosine monotherapy. Ann Intern Med 1994; 121: 263–8

    PubMed  CAS  Google Scholar 

  149. Gu Z, Gao Q, Parniak MA, et al. Novel mutation in the human immunodeficiency virus type 1 reverse transcriptase gene encodes cross resistance to 2′,3′-dideoxyinosine and 2′,3′-dide-oxycytidine. J Virol 1992; 66: 7128–35

    PubMed  CAS  Google Scholar 

  150. Gao Q, Gu ZX, Parniak MA, et al. The same mutation that encodes low-level human immunodeficiency virus type 1 resistance to 2′,3′-dideoxyinosine and 2′,3′-dideoxycytidine confers high-level resistance to the (-) enantiomer of 2′,3′-dideoxy-3′-thiacytidine. Antimicrob Agents Chemother 1993; 37: 1390–2

    Article  PubMed  CAS  Google Scholar 

  151. Lin HJ, Myers LE, et al. Multicenter evaluation of quantification methods for plasma human immunodeficiency virus type 1 RNA. J Infect Dis 1994; 170: 553–62

    Article  PubMed  CAS  Google Scholar 

  152. Fitzgibbon JE, Howell RM, Haberzettl C al. Human immunodeficiency virus type 1 pol gene mutations which caused decreased susceptibility to 2′,3′-dideoxycytidine. Antimicrob Agents Chemother 1992; 36: 153–7

    Article  PubMed  CAS  Google Scholar 

  153. Craig C, Moyle G. The development of resistance of HIV-1 to zalcitabine. AIDS 1997; 11: 271–9

    Article  PubMed  CAS  Google Scholar 

  154. Condra JH, Schleif WA, Blahy OM, et al. In vivo emergence of HIV-1 variants resistant to multiple protease inhibitors. Nature 1995; 374: 569–71

    Article  PubMed  CAS  Google Scholar 

  155. Jacobsen H, Hanggi M, Ott M, et al. In vivo resistance to a human immunodeficiency virus type 1 protease inhibitor: mutations, kinetics and frequencies. J Infect Dis 1996; 173: 1379–87

    Article  PubMed  CAS  Google Scholar 

  156. Patick AK, Duran M, Cao Y, et al. Genotypic and phenotypic characterisation of HIV-1 variants isolated from in vitro selection studies and from patients treated with the protease inhibitor, nelfinavir [abstract no. 29]. 5th International Workshop on HIV Drug Resistance; 1996 Jul 3–6: Whistler, British Columbia, Canada

  157. Tisdale M, Myers R, Najera I, et al. Analysis of resistant interactions with 141W94 (VX-478) and other protease inhibitors. 5th International Workshop on HIV Drug Resistance; 1996 Jul 3–6: Whistler, British Columbia, Canada

  158. Kinloch-de Loës S, Hirschel BJ, Hoen B, et al. A controlled trial of zidovudine in primary human immunodeficiency virus infection. N Engl J Med 1995; 333: 408–13

    Article  PubMed  Google Scholar 

  159. Wolinsky SM, Wike CM, Korber BT, et al. Selective transmission of human immunodeficiency virus type-1 variants from mother to infants. Science 1992; 255: 1134–7

    Article  PubMed  CAS  Google Scholar 

  160. Zhang L, MacKenzie P, Cleland A, et al. Selection for specific sequences in the external envelope protein of human immunodeficiency virus type 1 upon primary infection. J Virol 1993; 67: 3345–56

    PubMed  CAS  Google Scholar 

  161. Zhu T, Mo H, Wang N, et al. Genotypic and phenotypic characterization of HIV-1 in patients with primary infection. Science 1993; 261: 1179–81

    Article  PubMed  CAS  Google Scholar 

  162. Ho DD. Time to hit HIV, early and hard. N Engl J Med 1995; 333: 450–1

    Article  PubMed  CAS  Google Scholar 

  163. Pantaleo G, Graziosi C, Demarest JF, et al. HIV infection is active and progressive in lymphoid tissue during the clinically latent stage of disease. Nature 1993; 362: 355–8

    Article  PubMed  CAS  Google Scholar 

  164. Pantaleo G, Menzo S, Vaccarezza M, et al. Studies in subjects with long-term nonprogressive human immunodeficiency virus infection. N Engl J Med 1995; 332: 209–16

    Article  PubMed  CAS  Google Scholar 

  165. Cao Y, Qin L, Zhang L, et al. Virologic and immunologic characterization of long-term survivors of human immunodeficiency virus type 1 infection. N Engl J Med 1995; 332: 201–8

    Article  PubMed  CAS  Google Scholar 

  166. Hogervorst E, Jurriaans S, deWolf F, et al. Predictors for non- and slow progression in human immunodeficiency virus (HIV) type 1 infection: low viral RNA copy numbers in serum and maintenance of high HIV-1 p24-specific but not V3-specific antibody levels. J Infect Dis 1995; 171: 811–21

    Article  PubMed  CAS  Google Scholar 

  167. Mellors JW, Kingsley LA, Rinaldo CR, et al. Quantitation of HIV-1 RNA in plasma predicts outcome after seroconversion. Ann Intern Med 1995; 122: 573–9

    PubMed  CAS  Google Scholar 

  168. Luque F, Caruz A, Pineda JA, et al. Provirus load changes in untreated and zidovudine-treated human immunodeficiency virus type 1-infected patients. J Infect Dis 1994; 169: 267–73

    Article  PubMed  CAS  Google Scholar 

  169. Yerly S, Kaiser L, Baumberger C, et al. Early and prolonged decrease of viraemia in HTV-1-infected patients treated with didanosine. J Acquir Immune Defic Syndr 1995; 8: 358–64

    CAS  Google Scholar 

  170. Yerly S, Kaiser L, Mermillod B, et al. Response of HIV RNA to didanosine as a predictive marker of survival. AIDS 1995; 9: 159–63

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Kobler Centre, Chelsea and Westminster Hospital, 369 Fulham Road, London, SW10 9TH, England

    Graeme J. Moyle &  Brian G. Gazzard

  2. National Health and Medical Research Council and St Vincent’s Hospital, Sydney, NSW, Australia

    David A. Cooper

  3. Hospital Clinic Provencal, Barcelona, Spain

    José Gatell

Authors
  1. Graeme J. Moyle
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Brian G. Gazzard
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. David A. Cooper
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. José Gatell
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Moyle, G.J., Gazzard, B.G., Cooper, D.A. et al. Antiretroviral Therapy for HIV Infection. Drugs 55, 383–404 (1998). https://doi.org/10.2165/00003495-199855030-00005

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00003495-199855030-00005

Keywords

Search

Navigation